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Abstract
The maternally inherited mitochondrial DNA (mtDNA) is a circular 16,569-bp double stranded 
DNA that encodes 37 genes, twenty-four of which (2 rRNA and 22 tRNA) are necessary for 
transcription and translation of 13 polypeptides that are all subunits of respiratory chain. 
Pathogenic mutations of mtDNA cause respiratory chain dysfunction, and are the underlying 
defect in an ever-increasing number of mtDNA-related encephalomyopathies with distinct 
phenotypes. In this chapter, we present an overview of mtDNA mutations and describe the 
molecular techniques currently employed in our laboratory to detect two types of mtDNA 
mutations: Single-large scale rearrangements and point mutations.
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I. Introduction
The human mitochondrial genome is a 16,569-bp (base pair) circle of double stranded DNA. 
It contains 37 genes, which specify 2 ribosomal RNAs (rRNAs), 22 transfer RNAs (tRNAs), 
and 13 polypeptides (Fig. 1). All13 polypeptides encoded by mtDNA are components of the 
respiratory chain/oxidative phosphorylation system and include 7 subunits of complex I 
[NADH-coenzyme Q (CoQ) oxidoreductase], 1 subunit of complex III (CoQ cytochrome c 
oxidoreductase), 3 subunits of complex IV (cytochrome c oxidase), and two subunits of 
complex V (ATP synthase).
Each of these complexes also contains subunits encoded by nuclear genes, which are 
imported from the cytoplasm, assembled into holoenzymes with the mtDNA-encoded 
subunits, and embedded in the mitochondrial inner membrane. Complex II (succinate 
dehydrogenase-CoQ oxidoreductase) is encoded entirely by nuclear genes.
As mitochondria have a very dynamic multimembrane organization that facilitates the 
organelle’s distribution throughout the cell as a bioenergetic network, mtDNA is maintained 
in macromolecular assemblies called nucleoids at discrete sites throughout the mitochondrial 
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network. These nucleoids are protein-DNA assemblies, typically consisting of one or two 
copies of mtDNA and associated proteins (Kukat et al. 2011; Brown et al. 2011), that ensure 
the distribution and effective transmission of mtDNA (Bonekamp and Larsson, 2018).
There are several distinctive features of mtDNA that are relevant to the understanding of 
mtDNA-related disease. (1) At fertilization all mitochondria are contributed by oocytes; thus 
mtDNA is inherited only from the mother. Therefore, most mtDNA point mutations are 
maternally inherited: a woman carrying an mtDNA point mutation will transmit it to all her 
children, males as well as females, but only the daughters will transmit it to their progeny. 
However, while mtDNA itself is transmitted by the mother, disorders of mtDNA are not 
always inherited maternally. For example, large-scale single deletions in mtDNA are often 
sporadic and are not maternally inherited. Similarly mtDNA depletion and multiple deletion 
errors are often the result of mutation in nuclear genes that affect the integrity or quantity of 
mtDNA. As such, they are transmitted as autosomal recessive or autosomal dominant traits. 
(2) In contrast to nuclear genes, each consisting of one maternal and one paternal allele, 
there are hundreds or even thousands of copies of mtDNA in every cell. Thus, when there is 
a deleterious mutation, both normal and mutated mtDNAs may coexist within a patient’s 
tissues, a condition known as heteroplasmy. A critical number of mutant mtDNAs must be 
present before tissue dysfunction and clinical signs become apparent, the so-called threshold 
effect. Tissues with high requirement for oxidative metabolism, such as muscle, heart, eye, 
and brain have relatively low thresholds and are particularly vulnerable to mtDNA 
mutations. (3) At cell division, the proportion of mutant mtDNA in daughter cells can shift, 
a phenomenon termed or known as mitotic segregation. If and when the pathogenic 
threshold for a particular tissue is exceeded, the phenotype can change. Thus in a patient 
who is heteroplasmic for a pathogenic mutation, the clinical phenotype can change over the 
course of time.
II. MtDNA Mutations
Beginning in 1988, an ever-increasing number of mitochondrial diseases with distinct 
clinical phenotypes have been associated with mutations in mtDNA (reviewed in Schon, 
2000), almost all of which result in neurological or neuro-muscular disorders. These errors 
fall into two major classes: (1) large-scale rearrangements of mtDNA, and (2) point 
mutations in mtDNA. Large-scale single deletion of mtDNA are associated with three major 
clinical conditions: Kearns-Sayre syndrome (KSS), progressive external ophthalmoplegia 
(PEO), and Pearson syndrome (PS). Although dozens of different deletions have been 
described, each patient harbors only a single type of deletion and the number of deleted 
genome varies in different patients and in different tissues. Most patients reported with 
deletions in mtDNA have been sporadic; mothers of affected individuals and children of 
affected women are clinically unaffected and, when tested, have no detectable deletions 
(Graff et al., 2000: Larsson et al., 1992; Zeviani et al., 1990). This suggested that deletion 
arose de novo early in embryogenesis or ovum. However, there have been several reports of 
deletions that appear to have been transmitted maternally (Bernes et al., 1993; Boles et al., 
1997; Shanske et al., 2002). Thus, one needs to be cautious when counseling.
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Regarding mtDNA point mutations, as of to date, more than 200 pathogenic mtDNA point 
mutations have been documented and new ones are still being described (http://
www.mitomap.org). These point mutations are located in all regions of the genome. About 
two-thirds of them are located in tRNA genes. The rest are located in the polypeptide-coding 
genes, with a few in rRNA genes. Some of these mutations have been reported in only one 
or a few families, while others appear to be more common.). The first point mutation in a 
tRNA gene to be reported was an A-to-G transition at nt-8344 (A8344G) in patients with 
MERRF (Shoffner et al., 1990). This mutation is present in >90% of patients with MERRF, 
but other mutations have also been reported (Servidei, 2003). The A-to-G transition at 
nucleotide (nt) position 3243 (A3243G) is the most frequently encountered mtDNA point 
mutation and it is associated with a spectrum of clinical presentations. It was originally 
described in patients with MELAS (Goto et al., 1990), but was subsequently observed in 
maternal relatives of patients with MELAS who were often oligosymptomatic, presenting 
with diabetes, short stature, migraine headaches, hearing loss, or other features, either alone 
or in various combinations (DiMauro and Schon, 2001). The more common mutations in 
protein-coding genes are associated with two disorders: LHON (Leber hereditary optic 
neuropathy) and NARP/MILS (neuropathy, ataxia, and retinitis pigmentosa/maternally 
inherited Leigh syndrome). The G-to-A transition at nt-11,778 in patients with LHON, a 
disorder characterized by acute or subacute onset of bilateral visual loss in young adults, was 
the first point mutation in mtDNA to be reported (Wallace et al., 1988). LHON is associated 
with three primary mutations in genes encoding subunits of complex I of the respiratory 
chain—G3460A, G11778A, and T14484C (Servidei, 2003)—and these mutations are 
usually homoplasmic. A T-to-G mutation at nt-8993 (T8993G) in the mtDNA gene encoding 
ATPase 6 was initially described in patients with a maternally inherited multisystem disorder 
characterized by NARP (Holt et al., 1990). A family was subsequently reported in which an 
adult family member had the NARP syndrome and three children had MILS (Tatuch et al., 
1992). It is now well established that, for this particular mutation, there is a good correlation 
between the percentage of mutant genomes (i.e., degree of heteroplasmy) and the severity of 
the clinical phenotype. Patients with low levels of mutation are unaffected or have only mild 
symptoms, those with intermediate levels present with NARP, whereas those with very high 
levels (more than 95%) of mutation are associated with MILS (White et al., 1999). In 
addition to the T-to-G mutation, patients with a T-to-C substitution at the same position 
(T8993C) have been reported; they have milder clinical manifestations (DiMauro and 
Bonilla, 2003). Some patients with exercise intolerance often harbor mutations in protein-
coding genes causing defects in complexes I, III, or IV (Andreu et al., 1999; DiMauro and 
Schon, 2001). These patients are almost always sporadic, with no evidence of maternal 
transmission. Additionally, in most cases, these mutations are present only in muscle and are 
not detectable in blood or fibroblasts. It is believed that these mutations are somatic, that is, 
they are spontaneous events that occurred in muscle and do not affect germ line cells. 
Finally, pathogenic mutations in rRNA genes are rare. The most common one is in the 12S 
rRNA gene (A1555G) and has been reported in families with aminoglycoside induced 
deafness or nonsyndromic hearing loss (Prezant et al., 1993).
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III. Detecting mtDNA Large-Scale Single Deletion by Southern Blot 
analysis
Traditionally, single or multiple deletions in mtDNA are detected by Southern blot analysis 
and are best demonstrated by testing DNA isolated from muscle, since in most patients 
deletions are not detectable in DNA isolated from blood. To perform Southern blot analysis, 
total DNA is isolated, digested with restriction enzymes, separated on an agarose gel, 
transferred to a membrane (nitrocellulose or nylon), and incubated with a labeled 
(radioactive or non-radioactive) mtDNA probe that will hybridize only to the mtDNA. The 
bands are detected by autoradiography (when radiolabeled probe is employed) or by 
chemiluminescence imaging (when non-radioactive probe is employed). The fragments and 
their size(s) indicate whether only the normal-sized mtDNA (16.6 kb) is present or whether 
there is also a population of a smaller mtDNA, indicating a deletion. A detailed protocol for 
this methodology has previously been published in this book series (Schon et al., 2002; 
Naini and Shanske, 2007).
IV. Detecting mtDNA Large-Scale Single Deletions by Fluorescence In Situ 
Hybridization
a. Overview/rationale
Fluorescence in situ hybridization (FISH) provides a sequence-specific method to visualize 
competing wildtype (WT) mtDNA and large-scale deletions (Δ-mtDNAs) within the 
heteroplasmic cell. As a complementary method to traditional Southern blotting and 
emergent next generation sequencing methods for quantitating the levels of competing 
mtDNA species in a heteroplasmic cell population, two-color FISH is an adaptation of the 
method of Margineantu et al. (2000) using a combined set of fluorophore-labeled mtDNA-
specific probes to reveal the distribution of competing mtDNAs through fluorescence 
microscopy (Gilkerson et al. 2008). In heteroplasmic cells or tissue carrying WT and Δ -
mtDNAs, probes can be designed to hybridize both within the deleted mtDNA region and to 
a sequence common to both mtDNAs. By labeling the two probes with different 
fluorophores, WT mtDNAs will hybridize with both probes, while the Δ -mtDNA will 
hybridize with only the common probe (Santra et al. 2004). While DNA-binding dyes (such 
as DAPI) and immunolabeling for mtDNA-associated proteins such as TFAM can effectively 
track mtDNA nucleoids within the cell, the FISH method described here allows the 
sequence-specific visualization of WT and Δ-mtDNAs within heteroplasmic cells.
b. Materials/equipment/reagents
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Invitrogen Molecular Probes ARES DNA labeling kits in two varieties (e.g. AlexaFluor 488 





Cell preparation and hybridization—Cultured human cells
Glass coverslips
6-well cultured cell dishes





i. Amplify desired mtDNA sequences from total isolated cellular DNA. To ensure 
specificity, probe sequences are typically ~1.5 kb in length. Check a small 
amount via agarose gel electrophoresis to ensure the correct size of amplicon is 
generated. PCR reactions in 50 μL volume from 100 ng of template DNA may be 
pooled to provide sufficient yield for probe labeling.
ii. To prepare probe DNA for incorporation of aminoallyl dUTP and subsequent 
fluorescent labeling, prepare 1 μg DNA nick translation reactions, per 
manufacturer’s instructions. For optimal subsequent labeling of probe DNA, 
PCR amplicons should be nicked (but not degraded), yielding a smear ~100–200 
bp when visualized by agarose gel electrophoresis. Each new aliquot of DNase 
will require empirical determination of optimal concentration for use.
iii. Fluorescent labeling of amine-modified DNA allows the covalent linking of the 
aminoallyl dUTP (incorporated into the probe in step 2 above) with the reactive 
fluorophore. Reactions are set up per manufacturer’s instructions, followed by 
column purification and ethanol precipitation. Spectrophotometric readings at 
260 nm and the fluorophore excitation maximum allow determination of the 
specific labeling of the probe. Optimal probe labeling results in 1 dye molecule 
per 12–25 bases. Resuspend probe at 10 ng/μL stock following ethanol 
precipitation with 3 μg salmon sperm DNA and COT-1 DNA. Store probe stock 
at −80 degrees C.
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Cell preparation and hybridization
1. Grow cultured cells on glass coverslips in appropriate culture media until ~50% 
confluency. Wash cells twice with PBS, 2 min. each. Fix cells in 4% 
paraformaldehyde in PBS for 30 min. at room temperature. Wash twice with 
PBS, 2 min. each.
2. Dehydrate cells through 2 min. in 70%, 90%, 100% ethanol, followed by 
rehydration through 2 min. incubation in 90% ethanol, 70% ethanol, and PBS.
3. Treat coverslips with RNase (0.1 mg/mL in PBS), 1 hr. 37 degrees. If desired, a 
small volume of RNase (50–100 mLs) can be added to each coverslip followed 
by addition of a second coverslip to minimize volume. Wash twice with PBS, 2 
min. per wash.
4. Prehybridize coverslips in 2xSSC at 37 degrees, 30 min., followed by serial 
dehydration in 70%, 90%, and 100% ethanol, 2 min. each incubation. After 
100% ethanol, air dry coverslip.
5. Denature coverslip by incubation in 70% formamide in 2xSSC at 72 degrees C 
for 5 min. Use of a watch glass placed on a heating plate allows optimal heating 
of solution for denaturation. Dehydrate with ice-cold 70% ethanol (5 min.), 90% 
ethanol (1 min.), and 100% ethanol. Keep coverslip in 100% ethanol until probe 
is ready.
6. Dilute probe DNA to 2 ng/μL in hybridization solution (50% formamide, 10% 
dextran sulfates, 2xSSC). Denature 72 degrees 5 min. Snap cool and spin down.
7. Add probe to coverslip, ~15 μL per coverslip. Place anther coverslip to create a 
sandwich, avoiding air bubbles. Seal with rubber cement. Hybridize overnight at 
37 degrees in a humidified chamber (wet filter paper in a sealed petri dish).
8. Wash with 04xSSC +0.3% Tween-20, 72 degrees 5 min. Wash with 2xSSC 
+0.1%Tween-20 room temperature, 1 min. If desired, incubate with DAPI to 
visualize cell nuclei, 5 min. Wash 2 × 2 min. with 2xSSC.
9. Mount coverslip with 50% glycerol in PBS or other mounting medium.
Visualization and analysis—Cells may be visualized with any microscopy capable of 
visualizing the fluorophores utilized for hybridization. Typically, confocal microscopy 
provides high resolution images that eliminate out-of-focus cellular fluorescence. Within 
individual cells, mtDNA will be apparent as punctate foci, consistent with their assembly in 
nucleoids (Margineantu et al. 2002, Gilkerson et al. 2008). As nucleoids are typically ~100 
nm in diameter, a 100x objective (or 60x with optical zoom) is optimal to visualize mtDNAs 
at nucleoid-level resolution. Using two-color FISH, WT mtDNAs will hybridize with both 
red and green probes, while Δ-mtDNAs will hybridize with only one probe. Notably, WT 
mtDNAs will display both red and green probes with partial (but not complete) 
colocalization, an effect presumably due to the packaging of mtDNA into nucleoids. If 
desired, colocalization can be effectively quantitated using NIH ImageJ (Gilkerson et al. 
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2008). The images and colocalization data can be correlated with Southern blot and PCR 
data to analyze mtDNA heteroplasmic dynamics.
V. Detecting mtDNA Large-Scale Single Deletion by Next Generation 
Sequencing
Although Southern blot analysis is regarded as a gold standard technique for the detection of 
mitochondrial DNA rearrangements, the method suffers from several limitations. (1) It 
requires a relatively large amount of DNA (in μg range), (2) is labor intensive and time 
consuming (takes 2 to 3 days), and (3) does not give an accurate information as to the level 
of the heteroplasmy of the deleted DNA or the site of the breakpoints.
The introduction of massively parallel sequencing technology (next generation sequencing) 
and its application to the analysis of the whole mitochondrial genome, has overcome all the 
limitations associated with the mtDNA Southern blot analysis. The large amount of 
sequencing data generated by this methodology enables an accurate detection and 
quantification of not only mtDNA point mutations, but also of single-large scale deletions or 
multiple-deletions with their precise breakpoints. As an example, detecting a large mtDNA 
deletion by next generation sequencing in a patient harboring the mitochondrial DNA 
“common deletion” with 96% heteroplasmy is shown in Fig. 2. Detailed protocol of this 
methodology is described in the next section of this chapter.
VI. Detecting mtDNA Point Mutations by PCR/RFLP Analysis
Known point mutations in mtDNA are screened for by amplifying an Appropriate fragment 
of mtDNA by PCR, digesting with a diagnostic restriction enzyme and analyzing the 
fragment sizes on a gel. This involves the following steps: (1) oligonucleotide primers are 
designed to allow amplification of mtDNA encompassing the mutated site, (2) appropriate 
mtDNA fragments are amplified by PCR amplification in the presence of 32P dATP, (3) 
PCR products are digested with a restriction enzyme that will cleave normal versus mutated 
sequences differentially (i.e., restriction fragment length polymorphism or RFLP), (4) 
digestion products are electrophoresed through nondenaturing polyacrylamide gels, and (5) 
fragment sizes are detected by autoradiography. The primer sequences, amplification 
conditions, and detailed RFLP analyses to detect common point mutations of mtDNA can be 
found in the previous edition of this book series (Schon et al., 2002; Naini and Shanske, 
2007).
VII. Detecting Mitochondrial DNA Point Mutations and Rearrangements by 
Next Generation Sequencing (NGS)
1. Principle
The massively parallel sequencing of the entire length of mitochondrial genome by Next-
Generation Sequencing (NGS) methodology, which examines every nucleotide of the 
genome with very high coverage (>10,000) offers a powerful tool with unparalleled 
sensitivity for the detection of mtDNA mutations (point mutations as well as 
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rearrangements). This methodology not only identifies mtDNA mutations, but also 
determines, with high accuracy their level of heteroplasmy (Cui et al., 2013; Zhang et al., 
2012) which is important in the diagnosis of patients with mtDNA-related disorders. A few 
different versions of this technology have been published in recent years to sequence 
complete mitochondrial genome. They differ in the required initial step of mtDNA 
enrichment, which amplifies mitochondrial genome prior to sequencing. For example, in the 
method published by Palculict et al., 2016, one pair of primes amplifies complete sequence 
of mtDNA, whereas in the method published by Huang, 2011, two pairs of overlapping 
primers were used to amplify complete mtDNA sequence. Although mtDNA enrichment 
with one pair of primers is less labor intensive, it may however, increase the risk of primer 
dropouts and heteroplasmy miscalculation in the presence of mtDNA polymorphisms.
The method described here is an adaptation of the Illumina MiSeq protocol for sequencing 
of the human mitochondrial genome (Document # 15037958) and the method published by 
Huang, 2011. This method was validated and has been in use in our laboratory since 2013. 
In this assay, for amplification of mtDNA before sequencing, four sets of primer pairs are 
used. The first three primer pairs amplify the entire length of mtDNA in three overlapping 
fragments of 3968, 5513, and 7814 base pairs. The fourth primer, which amplifies the entire 
sequence of mitochondrial genome, is used for the detection of mtDNA large-scale deletions 
that could potentially interfere with the binding sites of the first three primer pairs. 
Following PCR amplifications, all fragments are purified and their sizes are verified on 
agarose gel electrophoresis. If no deletion is detected as verified by the size of fragment 
four, the three amplified segments are sequenced together. The three amplicons are 
quantitated and pooled before library preparation and subsequent sequencing on an Illumina 
MiSeq. Data analysis and reads alignment to the revised Cambridge Reference Sequence 
(rCRS) of human mtDNA are performed using NextGENe software (Softgenetics Inc.).
2. Reagents and Supplies
2.1. Long-Range PCR
1. 2.5 mM dNTP Mix (16 μl per sample).
2. 10X LA PCR Buffer II (10 μl per sample).
3. 96-well 0.3 ml PCR plate.
4. 200 μl PCR tubes.
5. Microseal ‘B’ Adhesive Seal (Bio-Rad, cat no. MSB-1001).
6. Nuclease-free water (45 μl per sample + volume to dilute primers).
7. Purified Human DNA (50 ng/ μL).
8. TaKaRa LA TaqDNA Polymerase (1μl per sample).
9. Custom made PCR primers: Four sets of primers are custom synthesized. and 
purified by Integrated DNA Technologies In. The sequence and their positions on 
mtDNA sequence are shown in Table 1.
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1. E-Gel (2%) with Ethidium bromide (Thermo Fisher Scientific).
2. E-Gel PowerBase (Thermo Fisher Scientific).
3. E-Imager (Thermo Fisher Scientific).
4. 10X BlueJuice Gel Loading Buffer - Invitrogen, Cat. 10816–015.
5. DNA Molecular Weight Marker II - Roche, Cat. 10236250001.
2.3. DNA Purification
1. Agencourt AMPure XP 60 ml kit – Beckman Coulter, Cat. A63881.
2. DNA LoBind Tube 1.5 mL - Eppendorf, Part # 022431021.
3. Ethanol 200 proof (absolute) for molecular biology (500 ml) – Thermo Fisher 
Scientific, cat. BP2818500.
4. Nuclease-Free Water - Life Technologies, Cat. AM9937.
5. Magnetic stand 96 – Ambion, Cat. AM10027.
6. Heat Block (Thermo Fisher Scientific).
2.4. DNA Quantification and Library Preparation
1. Lens paper, 4X6 in. – VW R, Cat. 52846–001.
2. Microseal ‘B’ adhesive seals – Bio-Rad, Cat. MSB-1001.
3. MicroTube (6×16mm), AFA fiber with snap-cap – Covaris, Cat. 520045.
4. MiSeq Reagent Kit v2 (300 cycle) – Illumina, Cat. MS-102–2002.
5. NaOH - Fisher Scientific, Cat. SS255–1.
6. Pipette tips (with filters).
7. Qubit assay tubes – Life Technologies, Cat. Q32856.
8. Qubit dsDNA BR assay kit – Life Technologies, Cat. Q32850.
9. TruSeq Nano DNA Sample Prep Kit v2 – Set A or B – Illumina, Cat. FC-122–
2001 or FC-122–2002.
10. Twin.Tec 96-well PCR plates – Eppendorf, Cat. 951020303.
11. Wizard® Genomic DNA purification kit - Promega, Cat. A1120.
2.5. Equipment
1. Centrifuge 5804 with rotor A-2-DW P – Eppendorf, Cat. 022628203.
2. Microcentrifuge 5424 with rotor FA-45–24-11 – Eppendorf, Cat. 022620401.
3. Nanodrop 2000 – Thermo Scientific.
4. Qubit 2.0 Fluorometer – Life Technologies, Cat. Q32866.
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5. S2 Sonication System – Covaris, Cat. S2.
6. SP Vortex Mixer – Baxter Scientific Products, Cat. S8223–1.
7. Thermal Cycler 2720 – Applied Biosystems, Cat. 4359659.
8. MiSeq instrument from Illumina.
9. Dell T7500 workstation with two 6 core Intel E5645 Processors (2.4gHz) and 
50Gb
10. DDR3 Ram using the NextGENe software from Softgenetics running on 
Windows 7 64 bit version.
3. Specimens
1. Blood: anti-coagulated, preferably with citrate or EDTA and less than a week 
old. Dilute extracted DNA with water to the concentration of 50 ng/ μL.
2. Urine specimen, minimum 20 mL of fresh urine is required. Urine specimens 
should be shipped at room temperature to the laboratory within 24 hours after 
collection. Dilute extracted DNA with water to the concentration of 50 ng/ μL.
3. Muscle biopsy specimens (>50mg) should be kept frozen from the time of 
biopsy to arrival to the lab. (Dilute extracted DNA with water to the 
concentration of 10 ng/ μL.
4. METHOD
A. Long-Range PCR (For 16 specimens, 9 hours)
1. Dilute each PCR primer to 5 μM with nuclease free water.
2. For each PCR primer (Mito1-F+Mito1-R; Mito2-F+Mito2-R; Mito3-F+Mito3-
R;Mito4-F+Mito4-R), prepare the following PCR master mix in the 200 μL PCR 
tube labeled with the appropriate primer pair number as outlined in the table 2.
3. Set up PCR on a plate on ice to prevent possible primer degradation from the 
polymerase activity.
4. Add 2 μL purified human DNA to each plate well (add 2 μL water to the blank 
well).
5. Add 48 μL of master mix from step 2 to each well, then pipette to mix and then 
seal the plate securely.
6. Place the plate on the pre-heated thermal cycler (to 94°C). Close the lid and run 
the following program: 98°C for 1 min → 35 cycles of (98°C for 10 sec → 72°C 
for 8:15 min) → 72°C for 10 min → 4°C HOLD indefinitely. At this stage, 
samples can be stored at −20 °C indefinitely.
7. Run 1 μL of each reaction product on a 1% E-Gel for 40 minutes.
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8. If optimum amplification is obtained (intense bands with correct sizes: Mito1: 
3968bp, Mito2: 5513bp, Mito3: 7814bp, and Mito4: 16484, proceed to the next 
step.
9. If size of amplicon 4 is as expected, proceed with quantification and pooling of 
PCR product 1, 2 and 3. Only these fragments will be sequenced.
10. If amplicons 1, 2 and 3 are of the proper size, but amplicon 4 is not, in addition 
to sequencing amplicons 1, 2 and 3, amplicon 4 has to be sequenced as a separate 
specimen, in order to identify heteroplasmic deletions that result in loss of primer 
binding sites 1F-R, 2F-R, or 3F-R in a subset of the mitochondrial DNA.
B. Amplicon Purification (20 min)
1. Gently shake the Agencourt AMPure XP bottle to resuspend any magnetic 
particles that may have settled. Add AMPure XP beads (1.6 X reaction volume) 
to each sample based.
2. Mix reagent and PCR reaction thoroughly by pipette mixing 10 times. Let the 
mixed samples incubate for 5 minutes at room temperature for maximum 
recovery.
3. Place the reaction plate on the magnetic stand for 2 minutes to separate beads 
from the solution.
4. Aspirate the cleared solution from the reaction plate and discard.
5. Dispense 200 μL of 70% ethanol to each well of the reaction plate and incubate 
for 30 seconds at room temperature. Aspirate the ethanol and discard. Repeat this 
step once for a total of two washes.
6. Off the magnet plate, add 40 μL of Resuspension Buffer to each well of the 
reaction plate and pipette mix 10 times. Let the samples incubate for 2 minutes.
7. Place the reaction plate onto the magnetic stand for 5 minutes to separate beads 
from the solution.
8. Transfer the eluent to a new plate.
C. Quantification and Pooling (55min)
1. Measure the concentration of each purified amplicon (1–3 and 4 if large deletion 
is suspected to be present) on Qbit fluorimeter and record concentrations.
2. For pooling three amplicons, in a spreadsheet, calculate the molar concentration 
and required volume of each amplicon to pool for fragmentation.
3. Store the pooled mtDNA (containing three equimolar purified amplicons) at −20 
°C. It is now ready for library preparation.
D. Library Preparation (5 hours)—For library preparation, amplification, validation 
and normalization, we use TruSeq Nano DNA Library preparation kit (Illumina part # 
15041877) according to manufacturer’s recommended protocol.
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E. Denaturing and Diluting Libraries and phiX Control for Sequencing on 
MiSeq Platform (40 min)
1. Denature and dilute DNA: In a microfuge tube, combine equal volume (5 μL) of 
4 nM library pool and 0.2 N NaOH to create a 2 nM dilution of the library pool.
2. Vortex briefly to mix, and then centrifuge at 280 xg for one minute.
3. Incubate for 5 min at room temperature to denature the DNA into single strands.
4. After 5 min incubation, add 990 μL of pre-chilled HT1 to the tube containing 
denatured DNA. This results in a 20 pM denatured library in 1N NaOH.
5. Place the denatured DNA on ice until you are ready to make the final dilution.
6. Dilute denatured DNA to 12.5 pM by combining 625 μL of DNA solution and 
375 μL of pre-chilled HT1 buffer. Vortex mix, spin and keep on ice.
7. Prepare PhiX control:
a. dilute the PhiX library with Elution Buffer to 4 nM:
b. Denature phiX control by combining 5 μL of each 4 nM PhiX library 
and freshly diluted 0.2 N NaOH in a microcentrifuge tube.
8. Vortex briefly to mix, then centrifuge at 280xg for one minute.
9. Incubate for five minutes at room temperature to denature the PhiX library into 
single stands.
10. After the 5 min incubation, add the following volume of pre-chilled HT1 buffer 
to the tube containing denatured PhiX library to result in a 20 pM PhiX library:
1. Denatured PhiX library (10 μL)
2. Pre-chilled HT1 (990 μL)
11. Dilute an aliquot of the 20 pM PhiX library to 12.5 pM as follows:
1. 20 pM denatured PhiX library (187.5 μL)
2. Pre-chilled HT1 (112.5 μL)
3. Vortex and spin the tube.
12. Mix sample library and PhiX control:
1. Combine the following volumes of denatured PhiX control library and 
your denatured sample library to result in a 20 % volume ratio:
2. Denatured sample library (800 μL)
3. Denatured PhiX control (200 μL)
13. Set the combined sample library and PhiX control aside on ice until you are 
ready to load it onto the MiSeq reagent cartridge.
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F. Performing the run on a MiSeq (26 hours)
1. Pierce the foil seal over the reservoir labeled Load Samples.
2. Pipette 600 μL of your sample libraries into the Load Samples reservoir.
3. Proceed to the run setup steps using the MiSeq control software interface.
4. Create a sample sheet and add your sample information by creating a blank row 
and entering the Sample ID and index ID (MID 1–12) for each sample.
5. Click Finish and choose the directory where it will be saved.
G. Starting the run
1. Review “Analysis Workflow”, and “Read Length”. These parameters are 
specified in the sample sheet.
2. Review the folder locations in the lower-left corner. If you need to change any 
folder locations, select Change Folders. When you have completed the changes, 
select Save and then Next.
3. Select Next. The Pre-Run Check screen opens.
4. The system performs a check of all run components, disk space, and network 
connections before you start the run. If any items do not pass the pre-run check, a 
message appears on the screen with instructions to correct the error. When all 
items successfully pass the pre-run check, you are ready to start your run.
H. Run evaluation—Sequencing analysis Viewer (SAV) application installed on MiSeq 
sequencer gives all run information. Two main measures determine whether the run is 
acceptable or needs to be repeated. 1) Greater than 70% of reads should have Q-score equal 
or greater 30 (Q≥30), and 2) the total yield should be greater than 16Mb per sample.
I. RESULTS ANALYSIS AND INTERPRETATION (2 hours)
Data is transferred to the workstation where it can be analyzed by NextGENe software 
version 2.3 run on 64-bit workstation and Windows 7 operating system. The following steps 
are taken to generate SNP reports:
1. Format conversion: using “Conversion” tool provided by NextGENe software to 
convert FASTQ format to FASTA format.
2. Data Analysis:
In Application page, three functions are specified as:
Instrument Type – Illumina.
Application Type - SNP/Indel.
Discovery Step- Sequence Alignment.
In Load data page: Reference file “NC_012920_1.gbk” is used.
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In Alignment page: set the mutant rate cut off 10% with the minimum coverage 
of 10. The other settings are set as default.
3. Results: After the software finishes the analysis, the NextGENe viewer window 
will open automatically
4. The results will be outputted as text file and vcf file. To generate mutation report, 
go to Toolbar, click on the transcript report icon and select “Show Transcript 
Report below Sequences”. The mutation table will display.
5. For the detection of large deletions use sequences obtained from amplification 
with PCR primer pairs 1–3 as well as PCR primer Pair 4. For determination of 
the exact coordinates of the missing genomic segment, run the analysis with the 
“Detect Structural Variations” tab checked. During such analysis reads that 
match over 0.1% of their length or greater than 15 nucleotides to two 
noncontiguous segments of the reference genome are stored in so called 
“Pseudo- Paired-End” sequence files. To identify the breakpoints, run NextGENe 
again using the sequences in the PseudoPairedEnd files as input files. The 
chimeric sequences are displayed in the NextGENe viewer in relation to the 
reference genome sequence making identification of the breakpoint possible. To 
do this, position the blue cross on the genomic region where the coverage drops 
dramatically; the sequences corresponding to this region will terminate at a 
single nucleotide. Repeat this on the other breakpoint on the right.
J. Troubleshooting
1. Input DNA quantification—Correct quantification of genomic DNA is essential. The 
ultimate success or failure of a library preparation strongly depends on using an accurately 
quantified amount of input DNA. Illumina recommends using fluorometric based methods 
for quantification including Qubit or PicoGreen to provide accurate quantification for 
dsDNA. Small volume pipetting can be a source of potential error in protocols that require 
generation of standard curves, such as PicoGreen assays or qPCR, or those that require small 
but precise volumes, such as the Agilent BioAnalyzer. If small volumes are unavoidable, 
then make sure that all pipettes used are precise and are correctly calibrated.
2. Master-mix reagent handling—Minimize freeze-thaw cycles. If you do not intend 
to consume the reagents in one use, dispense the reagent into aliquots after the initial thaw 
and refreeze the aliquots in order to avoid excessive freeze- thaw cycles. Add reagents in the 
order indicated in the TruSeq DNA Sample Preparation Guide. Care must be taken while 
adding the A-Tailing Mix (ATL) and Ligation Mix (LIG) due to the viscosity of the reagents.
3. Fragmentation—Problem: Incomplete shearing caused by too much DNA input.
Solution: Adhere to recommended starting amounts (1μg).
Problem: Increased size range.
Solution: Covaris problem, check Covaris with DNA of known quality (like Lambda).
Naini et al. Page 14













4. Library quality problems
1. Presence of adapter dimers.
Potential causes: Improper AMPure bead ratios, inefficient Ligation (too much 
input DNA, too little input DNA).
2. Additional peaks in Bioanalyzer trace.
Cause: SPRI bead carryover
Solution: Use a strong magnet for bead separation, pipette carefully during 
elution to avoid disturbing bead pellet
5. MiSeq run setup issues—Error: Initialization Failed.
Action: The option to re-initialize appears on the screen. Select Re-initialize.
Error: Fluidics check failed.
Action: Select Pump. When fluids have been pumped, select Restart Check.
Error: Disk space low.
Action: If disk space is low, a message appears indicating how much disk space is required. 
Use the Manage Files feature to clear the required space from the instrument computer.
Error: Network disconnected.
Action: Make sure the network cable is plugged into the instrument. If the network 
connection is not resolved; reboot the instrument by turning off the power switch. Wait at 
least 60 seconds, and then turn the instrument on using the power switch.
5. Poor quality MiSeq sequencing results—The performance characteristics of the 
sequencing are assessed in each run using Illumina provided controls. The controls are 
useful for identifying the specific mode of failure. The end repair control, A-Tailing control, 
and Ligase control reagents are used as controls for the enzymatic activities of the End 
Repair Mix, A- Tailing Mix, and DNA Ligase Mix, respectively. Each reagent contains 
double stranded DNA fragments designed to report the success or failure of a specific 
enzymatic activity used in the library preparation process. If a control’s sequence appears in 
the final sequencing data, it indicates that its corresponding step was successful. If it does 
not, or if it appears in substantially diminished numbers, it indicates the step failed. Illumina 
also provides a PhiX control library which is spiked in to the prepared sample library at a 
low concentration in order to help evaluate any clustering issues on the sequencing 
instrument.
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The human mitochondrial genome encodes for 13 mRNAs, 22 tRNAs, and 2 rRNAs. The 7 
subunits of NADH-ubiquinone oxidoreductase (ND), 3 subunits of cytochrome c oxidase 
(COX), cytochrome b (Cyt b), 2 subunits of ATP synthase (A), 22 tRNAs, and 2 rRNAs 
(12S and 16S) are shown. The origins of heavy (OH) and light (OL) strand replication, and 
the heavy (HSP) and light (LSP) strand transcriptional promoters are also shown.
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Detection of a large-scale (~5kb) deletion by NGS in a patient harboring the mtDNA 
“common deletion” with 96% heteroplasmy (panel A patient, panel B control). The 
nucleotide positions (X- axis) are according to rCRS reference mitochondrial genome. Y-
axis represents the coverage of each detected nucleotide.
Naini et al. Page 19

























Naini et al. Page 20
Table 1.
Primers sequences and their positions on mtDNA sequence.
Primer Sequence No. of nt Position on mtDNA
MTI-F1 5’ acatagcacattacagtcaaatcccttctcgtccc 3’ 35 16331–16365
MTI-R1 5’ tgagattgtttgggctactgctcgcagtgc 3’ 30 3729–3700
MTII-F2 5’ tactcaatcctctgatcagggtgagcatcaaactc 35 3646–3680
MTII-R2 5’ gcgtggattaaggcgacagcgatttctaggatagt 35 9158–9124
MTIII-F3 5’ tcatttttattgccacaactaacctcctcggact 3’ 35 8753–8787
MTIII-R3 5’ cgtgatgtcttatttaaggggaacgtgtgggctat 35 16566–16532
MTIV-F4 5’ tctatcaccctattaaccactcacgggagct 3’ 31 10–41
MTIV-R4 5’ gatacagttcactttagctacccccaagtgtt 3’ 32 16494–16462
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Table2
Composition of Long-Range PCR Master Mix for one primer Pair
Stock Volume/Rx Final Concentration in 50 μL PCR reaction
Nuclease Free Water 22.5 μL
2.5 mM dNTPs (from TaKaRa Kit) 5.0 μL 250 μM
10X LA PCR buffer (Mg2+)(from TaKaRa Kit) 5 μL 1x (2.5 mM Mg2+)
LA Taq enzyme (from TaKaRa Kit) 0.5 μL 1.25 U/25 μL
10μM Forward primer 5 μL 1.0 μ M
10μM Reverse primer 5 μL 1.0 μ M
Nuclease free water 5 μL
Total Volume 48.0 μL
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